CXCL10/IP-10: A missing link between inflammation and anti-angiogenesis in preeclampsia?

References

• Brosens I A, Robertson W B, Dixon H G. The role of the spiral arteries in the pathogenesis of pre-eclampsia. J Pathol 1970; 101: vi
   Web of Science ®Google Scholar
• Brosens I, Dixon H G, Robertson W B. Fetal growth retardation and the arteries of the placental bed. Br J Obstet Gynaecol 1977; 84: 656–663
   PubMedGoogle Scholar
• De Wolf F, Brosens I, Renaer M. Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension. Br J Obstet Gynaecol 1980; 87: 678–685
   PubMedGoogle Scholar
• Khong T Y, De Wolf F, Robertson W B, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049–1059
   PubMedGoogle Scholar
• Pijnenborg R, Anthony J, Davey D A, Rees A, Tiltman A, Vercruysse L, van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648–655
   PubMedGoogle Scholar
• Meekins J W, Pijnenborg R, Hanssens M, McFadyen I R, van Assche A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669–674
   PubMedGoogle Scholar
• Brosens J J, Pijnenborg R, Brosens I A. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: A review of the literature. Am J Obstet Gynecol 2002; 187: 1416–1423
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Kim Y M, Kusanovic J P, Hassan S, Erez O, Gotsch F, Than N G, Papp Z, Kim C J. Normal and abnormal transformation of the spiral arteries during pregnancy. J Perinat Med 2006; 34: 447–458
   PubMed Web of Science ®Google Scholar
• Campbell S, Diaz-Recasens J, Griffin D R, Cohen-Overbeek T E, Pearce J M, Willson K, Teague M J. New Doppler technique for assessing uteroplacental blood flow. Lancet 1983; 1: 675–677
   PubMed Web of Science ®Google Scholar
• Harrington K F, Campbell S, Bewley S, Bower S. Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1991; 42(Suppl)S14–S20
   PubMed Web of Science ®Google Scholar
• Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine antenatal scanning: Prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1993; 100: 989–994
   PubMedGoogle Scholar
• Harrington K, Cooper D, Lees C, Hecher K, Campbell S. Doppler ultrasound of the uterine arteries: The importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 1996; 7: 182–188
   PubMed Web of Science ®Google Scholar
• Dekker G A, Sibai B M. Etiology and pathogenesis of preeclampsia: Current concepts. Am J Obstet Gynecol 1998; 179: 1359–1375
   PubMed Web of Science ®Google Scholar
• Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides K H. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000; 96: 559–564
   PubMed Web of Science ®Google Scholar
• Papageorghiou A T, Yu C K, Bindra R, Pandis G, Nicolaides K H. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441–449
   PubMed Web of Science ®Google Scholar
• Papageorghiou A T, Yu C K, Nicolaides K H. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 383–396
   PubMed Web of Science ®Google Scholar
• Roberts J M, Taylor R N, Musci T J, Rodgers G M, Hubel C A, McLaughlin M K. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200–1204
   PubMed Web of Science ®Google Scholar
• Redman C W, Sacks G P, Sargent I L. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499–506
   PubMed Web of Science ®Google Scholar
• Bretelle F, Sabatier F, Blann A, D'Ercole C, Boutiere B, Mutin M, Boubli L, Sampol J, Dignat-George F. Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: Comparison with pre-eclampsia. BJOG 2001; 108: 1277–1282
   PubMed Web of Science ®Google Scholar
• Poston L, Chappell L C. Is oxidative stress involved in the aetiology of pre-eclampsia?. Acta Paediatr Suppl 2001; 90: 3–5
   PubMedGoogle Scholar
• Johnson M R, Anim-Nyame N, Johnson P, Sooranna S R, Steer P J. Does endothelial cell activation occur with intrauterine growth restriction?. BJOG 2002; 109: 836–839
   PubMed Web of Science ®Google Scholar
• Roberts J M, Lain K Y. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002; 23: 359–372
   PubMed Web of Science ®Google Scholar
• Redman C W, Sargent I L. Latest advances in understanding preeclampsia. Science 2005; 308: 1592–1594
   PubMed Web of Science ®Google Scholar
• Ness R B, Sibai B M. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006; 195: 40–49
   PubMed Web of Science ®Google Scholar
• Torry D S, Wang H S, Wang T H, Caudle M R, Torry R J. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539–1544
   PubMed Web of Science ®Google Scholar
• Taylor R N, Grimwood J, Taylor R S, McMaster M T, Fisher S J, North R A. Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177–182
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, Brichant J F, Pignon M R, Noel A, Schaaps J P, Cabrol D, Frankenne F, Foidart J M. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555–5563
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee K Y, Goncalves L F, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541–1547
   PubMed Web of Science ®Google Scholar
• Levine R J, Maynard S E, Qian C, Lim K H, England L J, Yu K F, Schisterman E F, Thadhani R, Sachs B P, Epstein F H, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers R W, Larkin R W, Gilmour C, Bodnar L M, Crombleholme W R, Ness R B, Roberts J M, Hubel C A. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: Relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895–4903
   PubMed Web of Science ®Google Scholar
• Levine R J, Lam C, Qian C, Yu K F, Maynard S E, Sachs B P, Sibai B M, Epstein F H, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992–1005
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y M, Bdolah Y, Lim K H, Yuan H T, Libermann T A, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–649
   PubMed Web of Science ®Google Scholar
• Barden A, Graham D, Beilin L J, Ritchie J, Baker R, Walters B N, Michael C A. Neutrophil CD11B expression and neutrophil activation in pre-eclampsia. Clin Sci (Lond) 1997; 92: 37–44
   PubMed Web of Science ®Google Scholar
• Haller H, Ziegler E M, Homuth V, Drab M, Eichhorn J, Nagy Z, Busjahn A, Vetter K, Luft F C. Endothelial adhesion molecules and leukocyte integrins in preeclamptic patients. Hypertension 1997; 29: 291–296
   PubMed Web of Science ®Google Scholar
• Sacks G P, Studena K, Sargent K, Redman C W. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998; 179: 80–86
   PubMed Web of Science ®Google Scholar
• Gervasi M T, Chaiworapongsa T, Pacora P, Naccasha N, Yoon B H, Maymon E, Romero R. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001; 185: 792–797
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Gervasi M T, Refuerzo J, Espinoza J, Yoshimatsu J, Berman S, Romero R. Maternal lymphocyte subpopulations (CD45RA+ and CD45RO+) in preeclampsia. Am J Obstet Gynecol 2002; 187: 889–893
   PubMed Web of Science ®Google Scholar
• Sunder-Plassmann G, Derfler K, Wagner L, Stockenhuber F, Endler M, Nowotny C, Balcke P. Increased serum activity of interleukin-2 in patients with pre-eclampsia. J Autoimmun 1989; 2: 203–205
   PubMed Web of Science ®Google Scholar
• Greer I A, Lyall F, Perera T, Boswell F, Macara L M. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: A mechanism for endothelial dysfunction?. Obstet Gynecol 1994; 84: 937–940
   PubMed Web of Science ®Google Scholar
• Vince G S, Starkey P M, Austgulen R, Kwiatkowski D, Redman C W. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995; 102: 20–25
   PubMedGoogle Scholar
• Conrad K P, Miles T M, Benyo D F. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998; 40: 102–111
   PubMed Web of Science ®Google Scholar
• Daniel Y, Kupferminc M J, Baram A, Jaffa A J, Fait G, Wolman I, Lessing J B. Plasma interleukin-12 is elevated in patients with preeclampsia. Am J Reprod Immunol 1998; 39: 376–380
   PubMed Web of Science ®Google Scholar
• Saito S, Umekage H, Sakamoto Y, Sakai M, Tanebe K, Sasaki Y, Morikawa H. Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia. Am J Reprod Immunol 1999; 41: 297–306
   PubMed Web of Science ®Google Scholar
• Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol 1999; 117: 550–555
   PubMed Web of Science ®Google Scholar
• Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. T helper 1- and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1999; 86: 165–170
   PubMed Web of Science ®Google Scholar
• Sakai M, Ogawa K, Shiozaki A, Yoneda S, Sasaki Y, Nagata K, Saito S. Serum granulysin is a marker for Th1 type immunity in pre-eclampsia. Clin Exp Immunol 2004; 136: 114–119
   PubMed Web of Science ®Google Scholar
• Bartha J L, Romero-Carmona R, Comino-Delgado R. Inflammatory cytokines in intrauterine growth retardation. Acta Obstet Gynecol Scand 2003; 82: 1099–1102
   PubMed Web of Science ®Google Scholar
• Neville L F, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8: 207–219
   PubMedGoogle Scholar
• Strieter R M, Polverini P J, Kunkel S L, Arenberg D A, Burdick M D, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348–27357
   PubMed Web of Science ®Google Scholar
• Strieter R M, Polverini P J, Arenberg D A, Kunkel S L. The role of CXC chemokines as regulators of angiogenesis. Shock 1995; 4: 155–160
   PubMed Web of Science ®Google Scholar
• Strieter R M, Polverini P J, Arenberg D A, Walz A, Opdenakker G, Van Damme J, Kunkel S L. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995; 57: 752–762
   PubMed Web of Science ®Google Scholar
• Rollins B J. Chemokines. Blood 1997; 90: 909–928
   PubMed Web of Science ®Google Scholar
• Luster A D. Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436–445
   PubMed Web of Science ®Google Scholar
• Belperio J A, Keane M P, Arenberg D A, Addison C L, Ehlert J E, Burdick M D, Strieter R M. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1–8
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217–242
   PubMed Web of Science ®Google Scholar
• Bernardini G, Ribatti D, Spinetti G, Morbidelli L, Ziche M, Santoni A, Capogrossi M C, Napolitano M. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003; 273: 83–101
   PubMed Web of Science ®Google Scholar
• Rosenkilde M M, Schwartz T W. The chemokine system—a major regulator of angiogenesis in health and disease. APMIS 2004; 112: 481–495
   PubMed Web of Science ®Google Scholar
• Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: The regulatory link between inflammation and angiogenesis. Trends Immunol 2004; 25: 201–209
   PubMed Web of Science ®Google Scholar
• Strieter R M, Burdick M D, Gomperts B N, Belperio J A, Keane M P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593–609
   PubMed Web of Science ®Google Scholar
• Charo I F, Ransohoff R M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610–621
   PubMed Web of Science ®Google Scholar
• Luster A D, Unkeless J C, Ravetch J V. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985; 315: 672–676
   PubMed Web of Science ®Google Scholar
• Luster A D, Ravetch J V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987; 166: 1084–1097
   PubMed Web of Science ®Google Scholar
• Luster A D, Ravetch J V. Genomic characterization of a gamma-interferon-inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol Cell Biol 1987; 7: 3723–3731
   PubMed Web of Science ®Google Scholar
• Kaplan G, Luster A D, Hancock G, Cohn Z A. The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med 1987; 166: 1098–1108
   PubMed Web of Science ®Google Scholar
• Gottlieb A B, Luster A D, Posnett D N, Carter D M. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 1988; 168: 941–948
   PubMed Web of Science ®Google Scholar
• Vanguri P, Farber J M. IFN and virus-inducible expression of an immediate early gene, crg-2/IP-10, and a delayed gene, I-A alpha in astrocytes and microglia. J Immunol 1994; 152: 1411–1418
   PubMed Web of Science ®Google Scholar
• Sarris A H, Esgleyes-Ribot T, Crow M, Broxmeyer H E, Karasavvas N, Pugh W, Grossman D, Deisseroth A, Duvic M. Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: An explanation for the epidermotropism of cutaneous T-cell lymphoma?. Blood 1995; 86: 651–658
   PubMed Web of Science ®Google Scholar
• Vanguri P. Interferon-gamma-inducible genes in primary glial cells of the central nervous system: Comparisons of astrocytes with microglia and Lewis with brown Norway rats. J Neuroimmunol 1995; 56: 35–43
   PubMed Web of Science ®Google Scholar
• Cassatella M A, Gasperini S, Calzetti F, Bertagnin A, Luster A D, McDonald P P. Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 1997; 27: 111–115
   PubMed Web of Science ®Google Scholar
• Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H, Murphy M, Liao F, Farber J, Cassatella M A. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999; 162: 4928–4937
   PubMed Web of Science ®Google Scholar
• Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Hollander G A, Piali L. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 2002; 8: 1414–1420
   PubMed Web of Science ®Google Scholar
• Cardozo A K, Proost P, Gysemans C, Chen M C, Mathieu C, Eizirik D L. IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 2003; 46: 255–266
   PubMed Web of Science ®Google Scholar
• Narumi S, Yoneyama H, Inadera H, Nishioji K, Itoh Y, Okanoue T, Matsushima K. TNF-alpha is a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1beta and IFN-gamma. Cytokine 2000; 12: 1007–1016
   PubMed Web of Science ®Google Scholar
• Kraft M, Riedel S, Maaser C, Kucharzik T, Steinbuechel A, Domschke W, Luegering N. IFN-gamma synergizes with TNF-alpha but not with viable H. pylori in up-regulating CXC chemokine secretion in gastric epithelial cells. Clin Exp Immunol 2001; 126: 474–481
   PubMed Web of Science ®Google Scholar
• Algood H M, Lin P L, Yankura D, Jones A, Chan J, Flynn J L. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol 2004; 172: 6846–6857
   PubMed Web of Science ®Google Scholar
• Villagomez M T, Bae S J, Ogawa I, Takenaka M, Katayama I. Tumour necrosis factor-alpha but not interferon-gamma is the main inducer of inducible protein-10 in skin fibroblasts from patients with atopic dermatitis. Br J Dermatol 2004; 150: 910–916
   PubMed Web of Science ®Google Scholar
• Hardaker E L, Bacon A M, Carlson K, Roshak A K, Foley J J, Schmidt D B, Buckley P T, Comegys M, Panettieri R A, Jr, Sarau H M, et al. Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: Participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease. FASEB J 2004; 18: 191–193
   PubMed Web of Science ®Google Scholar
• Sheng W S, Hu S, Ni H T, Rowen T N, Lokensgard J R, Peterson P K. TNF-alpha-induced chemokine production and apoptosis in human neural precursor cells. J Leukoc Biol 2005; 78: 1233–1241
   PubMed Web of Science ®Google Scholar
• Berthier-Vergnes O, Bermond F, Flacher V, Massacrier C, Schmitt D, Peguet-Navarro J. TNF-alpha enhances phenotypic and functional maturation of human epidermal Langerhans cells and induces IL-12 p40 and IP-10/CXCL-10 production. FEBS Lett 2005; 579: 3660–3668
   PubMed Web of Science ®Google Scholar
• Shin H S, Drysdale B E, Shin M L, Noble P W, Fisher S N, Paznekas W A. Definition of a lipopolysaccharide-responsive element in the 5′-flanking regions of MuRantes and crg-2. Mol Cell Biol 1994; 14: 2914–2925
   PubMed Web of Science ®Google Scholar
• Nazar A S, Cheng G, Shin H S, Brothers P N, Dhib-Jalbut S, Shin M L, Vanguri P. Induction of IP-10 chemokine promoter by measles virus: Comparison with interferon-gamma shows the use of the same response element but with differential DNA–protein binding profiles. J Neuroimmunol 1997; 77: 116–127
   PubMed Web of Science ®Google Scholar
• Cheng G, Nazar A S, Shin H S, Vanguri P, Shin M L. IP-10 gene transcription by virus in astrocytes requires cooperation of ISRE with adjacent kappaB site but not IRF-1 or viral transcription. J Interferon Cytokine Res 1998; 18: 987–997
   PubMed Web of Science ®Google Scholar
• Gasper N A, Petty C C, Schrum L W, Marriott I, Bost K L. Bacterium-induced CXCL10 secretion by osteoblasts can be mediated in part through toll-like receptor 4. Infect Immun 2002; 70: 4075–4082
   PubMed Web of Science ®Google Scholar
• Shen Q, Zhang R, Bhat N R. MAP kinase regulation of IP10/CXCL10 chemokine gene expression in microglial cells. Brain Res 2006; 1086: 9–16
   PubMed Web of Science ®Google Scholar
• Durand S H, Flacher V, Romeas A, Carrouel F, Colomb E, Vincent C, Magloire H, Couble M L, Bleicher F, Staquet M J, et al. Lipoteichoic acid increases TLR and functional chemokine expression while reducing dentin formation in in vitro differentiated human odontoblasts. J Immunol 2006; 176: 2880–2887
   PubMed Web of Science ®Google Scholar
• Ohmori Y, Hamilton T A. Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J Biol Chem 1993; 268: 6677–6688
   PubMed Web of Science ®Google Scholar
• Ohmori Y, Hamilton T A. The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J Immunol 1995; 154: 5235–5244
   PubMed Web of Science ®Google Scholar
• Osawa Y, Iho S, Takauji R, Takatsuka H, Yamamoto S, Takahashi T, Horiguchi S, Urasaki Y, Matsuki T, Fujieda S. Collaborative action of NF-kappaB and p38 MAPK is involved in CpG DNA-induced IFN-alpha and chemokine production in human plasmacytoid dendritic cells. J Immunol 2006; 177: 4841–4852
   PubMed Web of Science ®Google Scholar
• Park C, Lee S, Cho I H, Lee H K, Kim D, Choi S Y, Oh S B, Park K, Kim J S, Lee S J. TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: Differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression. Glia 2006; 53: 248–256
   PubMed Web of Science ®Google Scholar
• Hancock W W, Gao W, Csizmadia V, Faia K L, Shemmeri N, Luster A D. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975–980
   PubMed Web of Science ®Google Scholar
• Hancock W W, Lu B, Gao W, Csizmadia V, Faia K, King J A, Smiley S T, Ling M, Gerard N P, Gerard C. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515–1520
   PubMed Web of Science ®Google Scholar
• Segerer S, Cui Y, Eitner F, Goodpaster T, Hudkins K L, Mack M, Cartron J P, Colin Y, Schlondorff D, Alpers C E. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001; 37: 518–531
   PubMed Web of Science ®Google Scholar
• Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, Binotto G, Valente M, Trentin L, Semenzato G. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158: 1703–1711
   PubMed Web of Science ®Google Scholar
• Melter M, Exeni A, Reinders M E, Fang J C, McMahon G, Ganz P, Hancock W W, Briscoe D M. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558–2564
   PubMed Web of Science ®Google Scholar
• Zhao D X, Hu Y, Miller G G, Luster A D, Mitchell R N, Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: Association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002; 169: 1556–1560
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kaptanoglu L, Haddad W, Ivancic D, Alnadjim Z, Hurst S, Tishler D, Luster A D, Barrett T A, Fryer J. Donor T cell activation initiates small bowel allograft rejection through an IFN-gamma-inducible protein-10-dependent mechanism. J Immunol 2002; 168: 3205–3212
   PubMed Web of Science ®Google Scholar
• Rotondi M, Rosati A, Buonamano A, Lasagni L, Lazzeri E, Pradella F, Fossombroni V, Cirami C, Liotta F, La Villa G, et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant 2004; 4: 1466–1474
   PubMed Web of Science ®Google Scholar
• Hu H, Aizenstein B D, Puchalski A, Burmania J A, Hamawy M M, Knechtle S J. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432–437
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kaptanoglu L, Tang Y, Ivancic D, Rao S M, Luster A, Barrett T A, Fryer J. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 2004; 126: 809–818
   PubMed Web of Science ®Google Scholar
• Panzer U, Reinking R R, Steinmetz O M, Zahner G, Sudbeck U, Fehr S, Pfalzer B, Schneider A, Thaiss F, Mack M, et al. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 2004; 78: 1341–1350
   PubMed Web of Science ®Google Scholar
• Tatapudi R R, Muthukumar T, Dadhania D, Ding R, Li B, Sharma V K, Lozada-Pastorio E, Seetharamu N, Hartono C, Serur D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390–2397
   PubMed Web of Science ®Google Scholar
• Burns W R, Wang Y, Tang P C, Ranjbaran H, Iakimov A, Kim J, Cuffy M, Bai Y, Pober J S, Tellides G. Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-gamma-inducible chemokines in rejecting human arteries. Am J Transplant 2005; 5: 1226–1236
   PubMed Web of Science ®Google Scholar
• Lazzeri E, Rotondi M, Mazzinghi B, Lasagni L, Buonamano A, Rosati A, Pradella F, Fossombroni V, La Villa G, Gacci M, et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005; 79: 1215–1220
   PubMed Web of Science ®Google Scholar
• Sorensen T L, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik V A, Qin S, Rottman J, Sellebjerg F, Strieter R M, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807–815
   PubMed Web of Science ®Google Scholar
• Balashov K E, Rottman J B, Weiner H L, Hancock W W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999; 96: 6873–6878
   PubMed Web of Science ®Google Scholar
• Simpson J E, Newcombe J, Cuzner M L, Woodroofe M N. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000; 26: 133–142
   PubMed Web of Science ®Google Scholar
• Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192–198
   PubMed Web of Science ®Google Scholar
• Trebst C, Ransohoff R M. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: Opportunities and challenges. Arch Neurol 2001; 58: 1975–1980
   PubMedGoogle Scholar
• Christen U, McGavern D B, Luster A D, Von Herrath M G, Oldstone M B. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 2003; 171: 6838–6845
   PubMed Web of Science ®Google Scholar
• Christen U, Von Herrath M G. IP-10 and type 1 diabetes: A question of time and location. Autoimmunity 2004; 37: 273–282
   Web of Science ®Google Scholar
• Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 2002; 161: 195–206
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Rotondi M, Ferrari S M, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006; 93: 1226–1231
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Rotondi M, Ferrari S M, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154: 651–658
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari S M, Barani L, Ferrannini E, Serio M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006; 64: 189–195
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari S M, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004; 89: 5496–5499
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari S M, Paolicchi A, Ferrannini E, Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005; 152: 171–177
   PubMed Web of Science ®Google Scholar
• Keane M P, Arenberg D A, Lynch J P, III, Whyte R I, Iannettoni M D, Burdick M D, Wilke C A, Morris S B, Glass M C, DiGiovine B, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437–1443
   PubMed Web of Science ®Google Scholar
• Keane M P, Belperio J A, Arenberg D A, Burdick M D, Xu Z J, Xue Y Y, Strieter R M. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999; 163: 5686–5692
   PubMed Web of Science ®Google Scholar
• Strieter R M, Belperio J A, Keane M P. CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest 2002; 122: 298S–301S
   PubMed Web of Science ®Google Scholar
• Mach F, Sauty A, Iarossi A S, Sukhova G K, Neote K, Libby P, Luster A D. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999; 104: 1041–1050
   PubMed Web of Science ®Google Scholar
• Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, Koenig W. Chemokines and incident coronary heart disease: Results from the MONICA/KORA Augsburg case–cohort study, 1984–2002. Arterioscler Thromb Vasc Biol 2006; 26: 2147–2152
   PubMed Web of Science ®Google Scholar
• Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194–199
   PubMed Web of Science ®Google Scholar
• Strieter R M, Kunkel S L, Arenberg D A, Burdick M D, Polverini P J. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 1995; 210: 51–57
   PubMed Web of Science ®Google Scholar
• Luster A D, Greenberg S M, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995; 182: 219–231
   PubMed Web of Science ®Google Scholar
• Angiolillo A L, Sgadari C, Taub D D, Liao F, Farber J M, Maheshwari S, Kleinman H K, Reaman G H, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155–162
   PubMed Web of Science ®Google Scholar
• Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz C J. Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 2005; 12: 900–912
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–S22
   PubMed Web of Science ®Google Scholar
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159–167
   PubMed Web of Science ®Google Scholar
• Sibai B M, Ewell M, Levine R J, Klebanoff M A, Esterlitz J, Catalano P M, Goldenberg R L, Joffe G. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997; 177: 1003–1010
   PubMed Web of Science ®Google Scholar
• Alexander G R, Himes J H, Kaufman R B, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996; 87: 163–168
   PubMed Web of Science ®Google Scholar
• Nagaoka K, Nojima H, Watanabe F, Chang K T, Christenson R K, Sakai S, Imakawa K. Regulation of blastocyst migration, apposition, and initial adhesion by a chemokine, interferon gamma-inducible protein 10 kDa (IP-10), during early gestation. J Biol Chem 2003; 278: 29048–29056
   PubMed Web of Science ®Google Scholar
• Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon T I, Manaster I, et al. Decidual NK cells regulate key developmental processes at the human fetal–maternal interface. Nat Med 2006; 12: 1065–1074
   PubMed Web of Science ®Google Scholar
• Sarris A H, Broxmeyer H E, Wirthmueller U, Karasavvas N, Cooper S, Lu L, Krueger J, Ravetch J V. Human interferon-inducible protein 10: Expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J Exp Med 1993; 178: 1127–1132
   PubMed Web of Science ®Google Scholar
• Sasaki S, Yoneyama H, Suzuki K, Suriki H, Aiba T, Watanabe S, Kawauchi Y, Kawachi H, Shimizu F, Matsushima K, et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 2002; 32: 3197–3205
   PubMed Web of Science ®Google Scholar
• Loetscher M, Gerber B, Loetscher P, Jones S A, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP10 and mig: Structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963–969
   PubMed Web of Science ®Google Scholar
• Liu L, Callahan M K, Huang D, Ransohoff R M. Chemokine receptor CXCR3: An unexpected enigma. Curr Top Dev Biol 2005; 68: 149–181
   PubMed Web of Science ®Google Scholar
• Cole K E, Strick C A, Paradis T J, Ogborne K T, Loetscher M, Gladue R P, Lin W, Boyd J G, Moser B, Wood D E, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009–2121
   PubMed Web of Science ®Google Scholar
• Cox M A, Jenh C H, Gonsiorek W, Fine J, Narula S K, Zavodny P J, Hipkin R W. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: Differential binding to receptor states. Mol Pharmacol 2001; 59: 707–715
   PubMed Web of Science ®Google Scholar
• Sauty A, Colvin R A, Wagner L, Rochat S, Spertini F, Luster A D. CXCR3 internalization following T cell–endothelial cell contact: Preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol 2001; 167: 7084–7093
   PubMed Web of Science ®Google Scholar
• Colvin R A, Campanella G S, Sun J, Luster A D. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004; 279: 30219–30227
   PubMed Web of Science ®Google Scholar
• Dajotoy T, Andersson P, Bjartell A, Lofdahl C G, Tapper H, Egesten A. Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma. J Leukoc Biol 2004; 76: 685–691
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Levchenko A, Scott M L, Baltimore D. The IkappaB-NF-kappaB signaling module: Temporal control and selective gene activation. Science 2002; 298: 1241–1245
   PubMed Web of Science ®Google Scholar
• Taub D D, Lloyd A R, Conlon K, Wang J M, Ortaldo J R, Harada A, Matsushima K, Kelvin D J, Oppenheim J J. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993; 177: 1809–1814
   PubMed Web of Science ®Google Scholar
• Taub D D, Sayers T J, Carter C R, Ortaldo J R. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 1995; 155: 3877–3888
   PubMed Web of Science ®Google Scholar
• Dewald B, Moser B, Barella L, Schumacher C, Baggiolini M, Clark-Lewis I. IP-10, a gamma-interferon-inducible protein related to interleukin-8, lacks neutrophil activating properties. Immunol Lett 1992; 32: 81–84
   PubMed Web of Science ®Google Scholar
• Qin S, Rottman J B, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch A E, Moser B, Mackay C R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746–754
   PubMed Web of Science ®Google Scholar
• Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, Hauser A E, Hiepe F, Radbruch A, Arce S, Manz R A. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105: 3965–3971
   PubMed Web of Science ®Google Scholar
• Farber J M. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246–257
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Mackay C R, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187: 875–883
   PubMed Web of Science ®Google Scholar
• Piali L, Weber C, LaRosa G, Mackay C R, Springer T A, Clark-Lewis I, Moser B. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 1998; 28: 961–972
   PubMed Web of Science ®Google Scholar
• Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: Regulation, chemokine binding and gene localization. Eur J Immunol 1998; 28: 3696–3705
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Bianchi G, Bordignon P P, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray P A, Mantovani A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129–134
   PubMed Web of Science ®Google Scholar
• Yamamoto J, Adachi Y, Onoue Y, Adachi Y S, Okabe Y, Itazawa T, Toyoda M, Seki T, Morohashi M, Matsushima K, et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells. J Leukoc Biol 2000; 68: 568–574
   PubMed Web of Science ®Google Scholar
• Gangur V, Simons F E, Hayglass K T. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J 1998; 12: 705–713
   PubMed Web of Science ®Google Scholar
• Goldberg S H, van der Meer P, Hesselgesser J, Jaffer S, Kolson D L, Albright A V, Gonzalez-Scarano F, Lavi E. CXCR3 expression in human central nervous system diseases. Neuropathol Appl Neurobiol 2001; 27: 127–138
   PubMed Web of Science ®Google Scholar
• Christensen J E, Nansen A, Moos T, Lu B, Gerard C, Christensen J P, Thomsen A R. Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J Neurosci 2004; 24: 4849–4858
   PubMed Web of Science ®Google Scholar
• Wickham S, Lu B, Ash J, Carr D J. Chemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitis. J Neuroimmunol 2005; 162: 51–59
   PubMed Web of Science ®Google Scholar
• Sellner J, Dvorak F, Zhou Y, Haas J, Kehm R, Wildemann B, Meyding-Lamade U. Acute and long-term alteration of chemokine mRNA expression after anti-viral and anti-inflammatory treatment in herpes simplex virus encephalitis. Neurosci Lett 2005; 374: 197–202
   PubMed Web of Science ®Google Scholar
• Narumi S, Kaburaki T, Yoneyama H, Iwamura H, Kobayashi Y, Matsushima K. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 2002; 32: 1784–1791
   PubMed Web of Science ®Google Scholar
• Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 5885–5892
   PubMed Web of Science ®Google Scholar
• Klein R S. Regulation of neuroinflammation: The role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis. J Cell Biochem 2004; 92: 213–222
   PubMed Web of Science ®Google Scholar
• Klein R S, Izikson L, Means T, Gibson H D, Lin E, Sobel R A, Weiner H L, Luster A D. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 2004; 172: 550–559
   PubMed Web of Science ®Google Scholar
• Uguccioni M, Gionchetti P, Robbiani D F, Rizzello F, Peruzzo S, Campieri M, Baggiolini M. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 1999; 155: 331–336
   PubMed Web of Science ®Google Scholar
• Singh U P, Singh S, Taub D D, Lillard J W, Jr. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10 −/− mice. J Immunol 2003; 171: 1401–1406
   PubMed Web of Science ®Google Scholar
• Narumi S, Tominaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K, Itoh Y, Okanoue T. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997; 158: 5536–5544
   PubMed Web of Science ®Google Scholar
• Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kD protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum 2002; 46: 2730–2741
   PubMed Web of Science ®Google Scholar
• Rhode A, Pauza M E, Barral A M, Rodrigo E, Oldstone M B, Von Herrath M G, Christen U. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 2005; 175: 3516–3524
   PubMed Web of Science ®Google Scholar
• Lit L C, Wong C K, Tam L S, Li E K, Lam C W. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 209–215
   PubMed Web of Science ®Google Scholar
• Yang J, Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 2004; 9: 846–855
   PubMed Web of Science ®Google Scholar
• Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001; 107: 53–63
   PubMed Web of Science ®Google Scholar
• Soejima K, Rollins B J. A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. J Immunol 2001; 167: 6576–6582
   PubMed Web of Science ®Google Scholar
• Salcedo R, Resau J H, Halverson D, Hudson E A, Dambach M, Powell D, Wasserman K, Oppenheim J J. Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000; 14: 2055–2064
   PubMed Web of Science ®Google Scholar
• Datta D, Flaxenburg J A, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser A M, Briscoe D M, Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer. Cancer Res 2006; 66: 9509–9518
   PubMed Web of Science ®Google Scholar
• Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537–1549
   PubMed Web of Science ®Google Scholar
• Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir A M, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554–3561
   PubMed Web of Science ®Google Scholar
• Sgadari C, Angiolillo A L, Cherney B W, Pike S E, Farber J M, Koniaris L G, Vanguri P, Burd P R, Sheikh N, Gupta G, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A 1996; 93: 13791–13796
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Jaffe E S, Burd P R, Kanegane H, Kingma D W, Wilson W H, Longo D L, Tosato G. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein–Barr virus-positive lymphoproliferative disease. Blood 1997; 90: 4099–4105
   PubMed Web of Science ®Google Scholar
• Feldman A L, Friedl J, Lans T E, Libutti S K, Lorang D, Miller M S, Turner E M, Hewitt S M, Alexander H R. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99: 149–153
   PubMed Web of Science ®Google Scholar
• Arenberg D A, Kunkel S L, Polverini P J, Morris S B, Burdick M D, Glass M C, Taub D T, Iannettoni M D, Whyte R I, Strieter R M. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996; 184: 981–992
   PubMed Web of Science ®Google Scholar
• Sgadari C, Angiolillo A L, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877–3882
   PubMed Web of Science ®Google Scholar
• Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber J M, Liao F, Liu L, Tosato G. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998; 64: 384–392
   PubMed Web of Science ®Google Scholar
• Tannenbaum C S, Tubbs R, Armstrong D, Finke J H, Bukowski R M, Hamilton T A. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161: 927–932
   PubMed Web of Science ®Google Scholar
• Pertl U, Luster A D, Varki N M, Homann D, Gaedicke G, Reisfeld R A, Lode H N. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001; 166: 6944–6951
   PubMed Web of Science ®Google Scholar
• Koumandakis E, Koumandaki I, Kaklamani E, Sparos L, Aravantinos D, Trichopoulos D. Enhanced phagocytosis of mononuclear phagocytes in pregnancy. Br J Obstet Gynaecol 1986; 93: 1150–1154
   PubMedGoogle Scholar
• Naccasha N, Gervasi M T, Chaiworapongsa T, Berman S, Yoon B H, Maymon E, Romero R. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am J Obstet Gynecol 2001; 185: 1118–1123
   PubMed Web of Science ®Google Scholar
• Sacks G P, Redman C W, Sargent I L. Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: An intracellular flow cytometric analysis of peripheral blood mononuclear cells. Clin Exp Immunol 2003; 131: 490–497
   PubMed Web of Science ®Google Scholar
• Smarason A K, Gunnarsson A, Alfredsson J H, Valdimarsson H. Monocytosis and monocytic infiltration of decidua in early pregnancy. J Clin Lab Immunol 1986; 21: 1–5
   PubMedGoogle Scholar
• Melczer Z, Banhidy F, Csomor S, Toth P, Kovacs M, Winkler G, Cseh K. Influence of leptin and the TNF system on insulin resistance in pregnancy and their effect on anthropometric parameters of newborns. Acta Obstet Gynecol Scand 2003; 82: 432–438
   PubMed Web of Science ®Google Scholar
• Kupferminc M J, Peaceman A M, Wigton T R, Rehnberg K A, Socol M L. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994; 170: 1752–1757
   PubMed Web of Science ®Google Scholar
• Meekins J W, McLaughlin P J, West D C, McFadyen I R, Johnson P M. Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 1994; 98: 110–114
   PubMed Web of Science ®Google Scholar
• Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet 2001; 75: 243–249
   PubMed Web of Science ®Google Scholar
• Arriaga-Pizano L, Jimenez-Zamudio L, Vadillo-Ortega F, Martinez-Flores A, Herrerias-Canedo T, Hernandez-Guerrero C. The predominant Th1 cytokine profile in maternal plasma of preeclamptic women is not reflected in the choriodecidual and fetal compartments. J Soc Gynecol Investig 2005; 12: 335–342
   PubMedGoogle Scholar
• Dudley D J, Hunter C, Mitchell M D, Varner M W, Gately M. Elevations of serum interleukin-12 concentrations in women with severe pre-eclampsia and HELLP syndrome. J Reprod Immunol 1996; 31: 97–107
   PubMed Web of Science ®Google Scholar
• Hennessy A, Pilmore H L, Simmons L A, Painter D M. A deficiency of placental IL-10 in preeclampsia. J Immunol 1999; 163: 3491–3495
   PubMed Web of Science ®Google Scholar
• Omu A E, Al-Qattan F, Diejomaoh M E, Al-Yatama M. Differential levels of T helper cytokines in preeclampsia: Pregnancy, labor and puerperium. Acta Obstet Gynecol Scand 1999; 78: 675–680
   PubMed Web of Science ®Google Scholar
• Rinehart B K, Terrone D A, Lagoo-Deenadayalan S, Barber W H, Hale E A, Martin J N, Jr, Bennett W A. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 1999; 181: 915–920
   PubMed Web of Science ®Google Scholar
• Wang Y, Walsh S W. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996; 32: 157–169
   PubMed Web of Science ®Google Scholar
• Reynolds L P, Redmer D A. Utero-placental vascular development and placental function. J Anim Sci 1995; 73: 1839–1851
   PubMed Web of Science ®Google Scholar
• Kendall R L, Wang G, Thomas K A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324–328
   PubMed Web of Science ®Google Scholar
• Lyall F, Greer I A. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996; 1: 107–116
   PubMedGoogle Scholar
• Cheung C Y. Vascular endothelial growth factor: Possible role in fetal development and placental function. J Soc Gynecol Investig 1997; 4: 169–177
   PubMedGoogle Scholar
• Kupferminc M J, Daniel Y, Englender T, Baram A, Many A, Jaffa A J, Gull I, Lessing J B. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 1997; 38: 302–306
   PubMed Web of Science ®Google Scholar
• Lyall F, Greer I A, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997; 104: 223–228
   PubMedGoogle Scholar
• Vuorela P, Hatva E, Lymboussaki A, Kaipainen A, Joukov V, Persico M G, Alitalo K, Halmesmaki E. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997; 56: 489–494
   PubMed Web of Science ®Google Scholar
• Athanassiades A, Lala P K. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 1998; 19: 465–473
   PubMed Web of Science ®Google Scholar
• Clark D E, Smith S K, He Y, Day K A, Licence D R, Corps A N, Lammoglia R, Charnock-Jones D S. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540–1548
   PubMed Web of Science ®Google Scholar
• Taylor R N, de Groot C J, Cho Y K, Lim K H. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 17–31
   PubMedGoogle Scholar
• Desai J, Holt-Shore V, Torry R J, Caudle M R, Torry D S. Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod 1999; 60: 887–892
   PubMed Web of Science ®Google Scholar
• Hayman R, Brockelsby J, Kenny L, Baker P. Preeclampsia: The endothelium, circulating factor(s) and vascular endothelial growth factor. J Soc Gynecol Investig 1999; 6: 3–10
   PubMedGoogle Scholar
• Lash G E, Cartwright J E, Whitley G S, Trew A J, Baker P N. The effects of angiogenic growth factors on extravillous trophoblast invasion and motility. Placenta 1999; 20: 661–667
   PubMed Web of Science ®Google Scholar
• Reuvekamp A, Velsing-Aarts F V, Poulina I E, Capello J J, Duits A J. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 1019–1022
   PubMedGoogle Scholar
• Torry D S, Ahn H, Barnes E L, Torry R J. Placenta growth factor: Potential role in pregnancy. Am J Reprod Immunol 1999; 41: 79–85
   PubMed Web of Science ®Google Scholar
• Charnock-Jones D S, Burton G J. Placental vascular morphogenesis. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 953–968
   PubMed Web of Science ®Google Scholar
• Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich H A. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000; 80: 443–454
   PubMed Web of Science ®Google Scholar
• Ong S, Lash G, Baker P N. Angiogenesis and placental growth in normal and compromised pregnancies. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 969–980
   PubMed Web of Science ®Google Scholar
• Tidwell S C, Ho H N, Chiu W H, Torry R J, Torry D S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267–1272
   PubMed Web of Science ®Google Scholar
• Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher S J. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405–1423
   PubMed Web of Science ®Google Scholar
• Torry D S, Mukherjea D, Arroyo J, Torry R J. Expression and function of placenta growth factor: Implications for abnormal placentation. J Soc Gynecol Investig 2003; 10: 178–188
   PubMedGoogle Scholar
• Maynard S E, Min J Y, Merchan J, Lim K H, Li J, Mondal S, Libermann T A, Morgan J P, Sellke F W, Stillman I E, Epstein F H, Sukhatme V P, Karumanchi S A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–2351
   PubMed Web of Science ®Google Scholar
• Livingston J C, Chin R, Haddad B, McKinney E T, Ahokas R, Sibai B M. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000; 183: 1554–1557
   PubMed Web of Science ®Google Scholar
• Gaber L W, Spargo B H, Lindheimer M D. Renal pathology in pre-eclampsia. Baillieres Clin Obstet Gynaecol 1987; 1: 971–995
   PubMedGoogle Scholar
• Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis 1991; 17: 144–148
   PubMed Web of Science ®Google Scholar
• Wilczynski J R. Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia—the same basic mechanism?. Hum Immunol 2006; 67: 492–511
   PubMed Web of Science ®Google Scholar
• Irgens H U, Reisaeter L, Irgens L M, Lie R T. Long term mortality of mothers and fathers after pre-eclampsia: Population based cohort study. BMJ 2001; 323: 1213–1217
   PubMed Web of Science ®Google Scholar
• Meekins J W, Pijnenborg R, Hanssens M, van Assche A, McFadyen I R. Immunohistochemical detection of lipoprotein(a) in the wall of placental bed spiral arteries in normal and severe preeclamptic pregnancies. Placenta 1994; 15: 511–524
   PubMed Web of Science ®Google Scholar
• Katabuchi H, Yih S, Ohba T, Matsui K, Takahashi K, Takeya M, Okamura H. Characterization of macrophages in the decidual atherotic spiral artery with special reference to the cytology of foam cells. Med Electron Microsc 2003; 36: 253–262
   PubMedGoogle Scholar
• Harsem N K, Roald B, Braekke K, Staff A C. Acute atherosis in decidual tissue: Not associated with systemic oxidative stress in preeclampsia. Placenta 2007; 28(8–9)958–964
   PubMed Web of Science ®Google Scholar
• Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001; 88: 10K–15K
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–874
   PubMed Web of Science ®Google Scholar
• Hansson G K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695
   PubMed Web of Science ®Google Scholar
• Binder C J, Chang M K, Shaw P X, Miller Y I, Hartvigsen K, Dewan A, Witztum J L. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218–1226
   PubMed Web of Science ®Google Scholar
• Reape T J, Groot P H. Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213–225
   PubMed Web of Science ®Google Scholar
• Mach F. The role of chemokines in atherosclerosis. Curr Atheroscler Rep 2001; 3: 243–251
   PubMedGoogle Scholar
• Burke-Gaffney A, Brooks A V, Bogle R G. Regulation of chemokine expression in atherosclerosis. Vascul Pharmacol 2002; 38: 283–292
   PubMed Web of Science ®Google Scholar
• Shin W S, Szuba A, Rockson S G. The role of chemokines in human cardiovascular pathology: Enhanced biological insights. Atherosclerosis 2002; 160: 91–102
   PubMed Web of Science ®Google Scholar
• Sheikine Y, Hansson G K. Chemokines and atherosclerosis. Ann Med 2004; 36: 98–118
   PubMed Web of Science ®Google Scholar